Evidence map›Paper›PMID 37378711›Full record

SynthesisDigestive diseases and sciences2023

Efficacy and Safety of IL-12/23 and IL-23 Inhibitors for Crohn's Disease: Systematic Review and Meta-Analysis.

Sudheer Kumar Vuyyuru, Virginia Solitano, Malcolm Hogan, John K MacDonald, Alexa Zayadi, Claire E Parker, Bruce E Sands, Remo Panaccione, Neeraj Narula, Brian G Feagan and 3 more

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Digestive diseases and sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 4 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.The Cochrane database of systematic reviews · 2025
    Pooled it
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Observational
  12. Review
  13. Drug Development in Inflammatory Bowel Diseases: What Is Next?Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  14. Article
  15. Review
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 4 countries.

Sudheer Kumar VuyyuruDivision of Gastroenterology, Department of Medicine, Western University, 1151 Richmond St, London, ON, N6A 5C1, Canada.
Virginia SolitanoDivision of Gastroenterology, Department of Medicine, Western University, 1151 Richmond St, London, ON, N6A 5C1, Canada.
Malcolm HoganAlimentiv Inc., 100 Dundas St Suite 200, London, ON, N6A 5B6, Canada.
John K MacDonaldAlimentiv Inc., 100 Dundas St Suite 200, London, ON, N6A 5B6, Canada.
Alexa ZayadiAlimentiv Inc., 100 Dundas St Suite 200, London, ON, N6A 5B6, Canada.
Claire E ParkerAlimentiv Inc., 100 Dundas St Suite 200, London, ON, N6A 5B6, Canada.
Bruce E SandsDr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY, 10029, USA.
Remo PanaccioneDivision of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, 3330 Hospital Dr NW, Calgary, AB, T2N 4N1, Canada.
Neeraj NarulaDivision of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Brian G FeaganDivision of Gastroenterology, Department of Medicine, Western University, 1151 Richmond St, London, ON, N6A 5C1, Canada.
Siddharth SinghDivision of Gastroenterology, Department of Medicine, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA.
Vipul JairathDivision of Gastroenterology, Department of Medicine, Western University, 1151 Richmond St, London, ON, N6A 5C1, Canada.
Christopher MaAlimentiv Inc., 100 Dundas St Suite 200, London, ON, N6A 5B6, Canada. christopher.ma@ucalgary.ca.ORCID 0000-0002-4698-9948
Western University · CAIcahn School of Medicine at Mount Sinai · USMcMaster University · CASt Christopher's Hospice · GBUniversity of Calgary · CAUniversity of California San Diego · US

Funding

San Diego Biomedical Informatics Education & Research (SABER)T15LM011271 · NLM · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SHAMIM NEMATI · 2012 to 2026
$9.7M
NLM NIH HHS T15 LM011271
6 · The paper itself

Abstract

backgroundTargeting interleukin-23 (IL-23) is an important therapeutic strategy for Crohn's disease (CD).

aimsThis systematic review and meta-analysis assessed the efficacy and safety of selective IL-23p19 and IL-12/23p40 inhibitors in patients with moderate-to-severe CD.

methodsMEDLINE, Embase, and the Cochrane library (CENTRAL) were searched from inception to May 24, 2023, for randomized, placebo- or active comparator-controlled induction and/or maintenance trials of selective IL-23p19 and IL-12/23p40 inhibitors in pediatric and adult patients with CD. The primary outcome was the proportion of patients in clinical remission. Secondary outcomes were clinical response, endoscopic remission, endoscopic response, and safety. Data were pooled using a random-effects model. Risk of bias and certainty of evidence were assessed using the Cochrane risk of bias tool and the GRADE criteria, respectively.

resultsEighteen trials (n = 5561) were included. Most studies were rated as low risk of bias. Targeting IL-23 was significantly superior to placebo for inducing clinical (risk ratio [RR] = 1.87, 95% confidence interval [CI] 1.58-2.21) and endoscopic (RR = 3.20, 95%CI 2.17-4.70) remission and maintaining clinical remission (RR = 1.39, 95%CI 1.10-1.77) (GRADE high certainty evidence for all outcomes). Subgroup analysis showed that targeting IL-23 was superior to placebo for inducing clinical remission in biologic-naïve (RR = 2.20, 95%CI 1.46-3.32, I

conclusionTargeting IL-23 is effective and safe for inducing and maintaining clinical and endoscopic remission in patients with moderate-to-severe CD.

Indexed as

Biological ProductsCrohn DiseaseAdultChildHumansInterleukin-12Interleukin-23Interleukin-23 Subunit p19Interleukin InhibitorsRemission InductionBiological ProductsInterleukin-12Interleukin-23Interleukin-23 Subunit p19Interleukin InhibitorsBiologic therapyCrohn’s diseaseInflammatory bowel diseaseInterleukin-23 inhibitorsRisankizumabUstekinumab

Identifiers

PMID37378711
PMCPMC10981469
OpenAlexW4382345336

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.